REGN – Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.REGN
$585.65Name : Regeneron Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $64,026,189,824.00
EPSttm : 38.35
Regeneron Pharmaceuticals, Inc.
$585.65
4.09%$24.99Float Short %
3.08
Margin Of Safety %
59
Put/Call OI Ratio
0.84
EPS Next Q Diff
-1.71
EPS Last/This Y
1.57
EPS This/Next Y
4.48
Price
610.64
Target Price
934.77
Analyst Recom
1.75
Performance Q
-14.28
Relative Volume
1.1
Beta
0.42
Ticker: REGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | REGN | 687 | 0.89 | 0.94 | 34064 |
| 2025-03-06 | REGN | 699.68 | 0.88 | 1.04 | 34299 |
| 2025-03-07 | REGN | 707.51 | 0.89 | 0.53 | 34711 |
| 2025-03-10 | REGN | 744.81 | 0.90 | 0.57 | 34443 |
| 2025-03-11 | REGN | 717.41 | 0.92 | 0.62 | 35147 |
| 2025-03-12 | REGN | 689.03 | 0.91 | 0.11 | 35450 |
| 2025-03-13 | REGN | 681 | 0.80 | 0.54 | 38488 |
| 2025-03-14 | REGN | 666.6 | 0.80 | 0.53 | 38882 |
| 2025-03-17 | REGN | 678.15 | 0.81 | 0.60 | 38403 |
| 2025-03-18 | REGN | 664.37 | 0.80 | 0.64 | 38899 |
| 2025-03-19 | REGN | 672.67 | 0.80 | 0.86 | 39081 |
| 2025-03-20 | REGN | 661.18 | 0.80 | 1.45 | 39379 |
| 2025-03-21 | REGN | 659.48 | 0.79 | 1.29 | 39276 |
| 2025-03-24 | REGN | 660.86 | 0.82 | 0.21 | 36876 |
| 2025-03-25 | REGN | 633 | 0.86 | 0.67 | 36482 |
| 2025-03-26 | REGN | 639.58 | 0.83 | 0.42 | 38094 |
| 2025-03-27 | REGN | 635.26 | 0.81 | 2.87 | 38898 |
| 2025-03-28 | REGN | 637.72 | 0.81 | 1.68 | 38984 |
| 2025-03-31 | REGN | 634.04 | 0.85 | 0.91 | 37761 |
| 2025-04-01 | REGN | 616.29 | 0.85 | 1.14 | 38126 |
| 2025-04-02 | REGN | 625.24 | 0.84 | 0.82 | 38430 |
| 2025-04-03 | REGN | 610.88 | 0.84 | 1.80 | 38686 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | REGN | 686.77 | 0.5 | 87.2 | 43.09 |
| 2025-03-06 | REGN | 698.52 | 0.5 | 93.2 | 43.09 |
| 2025-03-07 | REGN | 707.59 | 0.5 | 74.8 | 43.09 |
| 2025-03-10 | REGN | 745.17 | -2.0 | 286.3 | 42.83 |
| 2025-03-11 | REGN | 718.56 | -2.0 | -179.4 | 42.83 |
| 2025-03-12 | REGN | 688.90 | -2.0 | -208.7 | 42.83 |
| 2025-03-13 | REGN | 680.61 | -2.0 | -62.3 | 42.83 |
| 2025-03-14 | REGN | 666.87 | -2.0 | -100.9 | 42.83 |
| 2025-03-17 | REGN | 678.42 | -2.0 | 97.6 | 42.83 |
| 2025-03-18 | REGN | 664.96 | -2.0 | -99.2 | 42.64 |
| 2025-03-19 | REGN | 672.36 | -2.0 | 64.7 | 42.64 |
| 2025-03-20 | REGN | 662.62 | -2.0 | -70.9 | 42.64 |
| 2025-03-21 | REGN | 658.10 | -2.0 | -30.4 | 42.64 |
| 2025-03-24 | REGN | 661.00 | -2.0 | 26.1 | 42.64 |
| 2025-03-25 | REGN | 634.14 | -2.0 | -216.2 | 42.64 |
| 2025-03-26 | REGN | 640.14 | -3.2 | 49.3 | 42.62 |
| 2025-03-27 | REGN | 635.27 | -3.2 | -41.4 | 42.62 |
| 2025-03-28 | REGN | 637.36 | -3.2 | 11.8 | 42.62 |
| 2025-03-31 | REGN | 634.23 | -3.2 | -27.1 | 42.62 |
| 2025-04-01 | REGN | 617.00 | -3.1 | -145.5 | 42.58 |
| 2025-04-02 | REGN | 625.60 | -3.5 | 73.3 | 42.47 |
| 2025-04-03 | REGN | 610.64 | -3.5 | -128.4 | 42.47 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | REGN | -0.08 | -0.09 | 2.09 |
| 2025-03-06 | REGN | -0.05 | -0.09 | 2.09 |
| 2025-03-07 | REGN | -0.05 | -0.09 | 2.09 |
| 2025-03-10 | REGN | -0.05 | 0.43 | 2.09 |
| 2025-03-11 | REGN | -0.05 | 0.43 | 2.09 |
| 2025-03-12 | REGN | -0.05 | 0.43 | 2.43 |
| 2025-03-13 | REGN | -0.05 | 0.43 | 2.43 |
| 2025-03-14 | REGN | -0.05 | 0.43 | 2.43 |
| 2025-03-17 | REGN | -0.05 | 0.51 | 2.43 |
| 2025-03-18 | REGN | -0.05 | 0.51 | 2.43 |
| 2025-03-19 | REGN | -0.05 | 0.51 | 2.43 |
| 2025-03-20 | REGN | -0.05 | 0.51 | 2.43 |
| 2025-03-21 | REGN | -0.05 | 0.51 | 2.43 |
| 2025-03-24 | REGN | -0.05 | 0.57 | 2.43 |
| 2025-03-25 | REGN | -0.05 | 0.57 | 2.43 |
| 2025-03-26 | REGN | -0.05 | 0.57 | 3.08 |
| 2025-03-27 | REGN | -0.05 | 0.57 | 3.08 |
| 2025-03-28 | REGN | -0.05 | 0.57 | 3.08 |
| 2025-03-31 | REGN | -0.05 | 0.57 | 3.08 |
| 2025-04-01 | REGN | -0.05 | 0.57 | 3.08 |
| 2025-04-02 | REGN | -0.05 | 0.57 | 3.08 |
| 2025-04-03 | REGN | -0.05 | 0.57 | 3.08 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
12.07
Avg. EPS Est. Current Quarter
9.26
Avg. EPS Est. Next Quarter
10.36
Insider Transactions
-0.05
Institutional Transactions
0.57
Beta
0.42
Average Sales Estimate Current Quarter
3396
Average Sales Estimate Next Quarter
3579
Fair Value
971.62
Quality Score
99
Growth Score
85
Sentiment Score
38
Actual DrawDown %
49.6
Max Drawdown 5-Year %
-48.7
Target Price
934.77
P/E
15.95
Forward P/E
13.3
PEG
2.73
P/S
4.7
P/B
2.28
P/Free Cash Flow
18.22
EPS
38.29
Average EPS Est. Cur. Y
42.47
EPS Next Y. (Est.)
46.95
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
31.07
Relative Volume
1.1
Return on Equity vs Sector %
-4.8
Return on Equity vs Industry %
8.1
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.62
EBIT Estimation
-128.4
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15106
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGN – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGN – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGN – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGN – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading